UBS Group Has Lowered Expectations for Owens & Minor (NYSE:OMI) Stock Price

Owens & Minor (NYSE:OMI) had its target price reduced by UBS Group from $28.00 to $25.00 in a research note issued to investors on Tuesday morning,Benzinga reports. They currently have a buy rating on the stock.

A number of other equities analysts also recently weighed in on the company. Citigroup cut their target price on Owens & Minor from $21.00 to $18.50 and set a “buy” rating on the stock in a research note on Tuesday. Robert W. Baird lowered their target price on shares of Owens & Minor from $19.00 to $14.00 and set a “neutral” rating on the stock in a report on Tuesday. StockNews.com cut shares of Owens & Minor from a “buy” rating to a “hold” rating in a report on Monday, August 26th. JPMorgan Chase & Co. decreased their price target on shares of Owens & Minor from $22.00 to $18.00 and set an “underweight” rating on the stock in a report on Wednesday, August 21st. Finally, Barclays reduced their target price on Owens & Minor from $18.00 to $14.00 and set an “equal weight” rating on the stock in a research note on Tuesday. Two investment analysts have rated the stock with a sell rating, five have assigned a hold rating and two have issued a buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $18.50.

Owens & Minor Stock Performance

Shares of Owens & Minor stock opened at $12.90 on Tuesday. The firm has a market cap of $994.72 million, a price-to-earnings ratio of -19.85, a price-to-earnings-growth ratio of 0.47 and a beta of 0.41. The stock’s 50-day moving average is $14.30 and its 200-day moving average is $15.98. Owens & Minor has a one year low of $11.42 and a one year high of $28.35. The company has a debt-to-equity ratio of 2.11, a current ratio of 1.09 and a quick ratio of 0.51.

Owens & Minor (NYSE:OMI) last issued its quarterly earnings results on Monday, November 4th. The company reported $0.42 EPS for the quarter, beating analysts’ consensus estimates of $0.41 by $0.01. Owens & Minor had a positive return on equity of 14.60% and a negative net margin of 0.46%. The company had revenue of $2.72 billion for the quarter, compared to analyst estimates of $2.68 billion. During the same period in the previous year, the company posted $0.44 earnings per share. The company’s quarterly revenue was up 5.0% compared to the same quarter last year. Equities analysts predict that Owens & Minor will post 1.49 earnings per share for the current fiscal year.

Institutional Trading of Owens & Minor

A number of large investors have recently made changes to their positions in OMI. ProShare Advisors LLC grew its holdings in Owens & Minor by 7.4% during the 1st quarter. ProShare Advisors LLC now owns 15,021 shares of the company’s stock valued at $416,000 after purchasing an additional 1,029 shares during the last quarter. Texas Permanent School Fund Corp grew its holdings in Owens & Minor by 1.8% during the 1st quarter. Texas Permanent School Fund Corp now owns 66,953 shares of the company’s stock valued at $1,855,000 after purchasing an additional 1,156 shares during the last quarter. DekaBank Deutsche Girozentrale grew its holdings in Owens & Minor by 76.6% during the 2nd quarter. DekaBank Deutsche Girozentrale now owns 3,126 shares of the company’s stock valued at $43,000 after purchasing an additional 1,356 shares during the last quarter. Arizona State Retirement System boosted its position in Owens & Minor by 7.7% in the 2nd quarter. Arizona State Retirement System now owns 20,371 shares of the company’s stock valued at $275,000 after buying an additional 1,449 shares during the period. Finally, Quarry LP boosted its position in Owens & Minor by 290.1% in the 2nd quarter. Quarry LP now owns 2,099 shares of the company’s stock valued at $28,000 after buying an additional 1,561 shares during the period. 98.04% of the stock is currently owned by institutional investors.

About Owens & Minor

Owens & Minor, Inc, together with its subsidiaries, operates as a healthcare solutions company worldwide. It operates through Products & Healthcare Services and Patient Direct segments. The Products & Healthcare Services segment offers a portfolio of products and services to healthcare providers and manufacturers.